<DOC>
	<DOCNO>NCT00574600</DOCNO>
	<brief_summary>The purpose study evaluate safety immune response experimental DNA HIV vaccine follow boost experimental modify vaccinia HIV vaccine ( MVA ) HIV uninfected adult .</brief_summary>
	<brief_title>Safety Immune Response Two HIV Vaccines : SAAVI DNA-C2 Boosted With SAAVIMVA-C , HIV-Negative Adults</brief_title>
	<detailed_description>The worldwide HIV/AIDS epidemic may control development utilization safe effective vaccine prevent HIV infection . Due high prevalence HIV-1 subtype C southern Africa , South African AIDS Vaccine Initiative ( SAAVI ) , HIV Vaccine Trials Network ( HVTN ) National Institute Allergy Infectious Diseases ( NIAID ) evaluate two subtype C HIV vaccine , SAAVI DNA-C2 SAAVI MVA-C study . These two vaccine use together prime-boost regimen . The SAAVI DNA-C2 vaccine multigene DNA vaccine consist two DNA plasmid equal amount express HIV-1 subtype C polyprotein comprise Gag-Reverse Transcriptase-Tat-Nef HIV-1 subtype C truncate Env . SAAVI MVA-C recombinant MVA vaccine express immunogen SAAVI DNA-C2 vaccine . MVA highly attenuate vaccinia virus . The purpose study evaluate safety immunogenicity experimental DNA HIV vaccine , SAAVI DNA C2 , follow boost experimental recombinant MVA HIV vaccine , SAAVI MVA-C , HIV uninfected adult . Participants actively participate study 12 month contact asked question health annually 3 year follow initial study injection . Participants randomly assign receive either SAAVI prime-boost preventive vaccine regimen placebo . Vaccination SAAVI DNA-C2 vaccine occur Months 0 , 1 , 2 ; boost vaccination SAAVI MVA-C vaccine occur Months 4 5 . Additional study visit occur Weeks 2 , 6 , 10 , 16 , 18 , 20 Days 147 , 154 , 273 , 364 . Study procedure include physical exam , blood urine collection , HIV testing , electrocardiogram , questionnaire . Some blood collect participant store used future research . Risk-reduction counseling conduct study visit .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Laboratory test result within specified range [ complete blood count , chemistry , cardiac troponin T , urinalysis ] Good general health HIV1 2 uninfected Have access participate HIV Vaccine Trials Unit ( HVTU ) willing follow duration study Willing receive HIV test result Negative hepatitis B surface antigen Negative hepatitis C virus ( HCV ) antibodies OR negative HCV PCR antiHCV test positive Willing use acceptable form contraception least 21 day prior enrollment duration study History vaccination smallpox HIV vaccine prior HIV vaccine trial Immunosuppressive medication within 168 day prior first study vaccination Blood product within 120 day prior first study vaccination Immunoglobulin within 60 day prior first study vaccination Live attenuate vaccine within 30 day prior first study vaccination schedule within 14 day vaccination ( e.g. , measles , mumps , rubella [ MMR ] ; oral polio vaccine [ OPV ] ; varicella ; yellow fever ; influenza vaccine nasal form ) Investigational research agent within 30 day prior first study vaccination Any vaccine live attenuate vaccine within 14 day prior first study vaccination Allergy treatment antigen injection within 30 day prior first vaccination schedule within 14 day vaccination Received investigational research agent within 30 day prior first vaccination Current tuberculosis ( TB ) prophylaxis therapy Recreational cocaine methamphetamine use within last 12 month prior first study vaccination Clinically significant medical condition , abnormal physical exam finding , abnormal laboratory result , past medical history may affect current health . More information criterion find protocol . Any medical , psychiatric , social , jobrelated condition would interfere study Serious adverse reaction vaccine . Participants adverse reaction pertussis vaccine child exclude . Hypersensitivity egg egg product Electrocardiogram ( ECG ) clinically significant finding . More information criterion find protocol . Risk factor heart disease . More information criterion find protocol . History current heart disease . More information criterion find protocol . Autoimmune disease immunodeficiency Active syphilis infection . Participants fully treat syphilis least 6 month prior study entry exclude . Unstable asthma . More information criterion find protocol . Diabetes mellitus type 1 2 . Participants history isolate gestational diabetes exclude . History thyroid removal thyroid disease require treatment 12 month prior study entry Serious angioedema within past 3 year require medication within 2 year study entry Hypertension wellcontrolled Body mass index ( BMI ) 40 Bleeding disorder Cancer . Participants surgically remove cancer unlikely recur exclude . Seizure disorder require medication within last 3 year Absence spleen Certain abnormal laboratory value Psychiatric condition would interfere compliance protocol Other condition , opinion investigator , would interfere study Pregnancy breastfeed</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>HIV Seronegativity</keyword>
	<keyword>HIV Preventive Vaccine</keyword>
</DOC>